RATIONALE: A common treatment strategy for pediatric attention deficit/hyperactivity disorder (ADHD) and major depressive disorder (MDD) is combined methylphenidate (MPH) and fluoxetine (FLX). This has raised concerns because MPH + FLX treatment may have pharmacodynamic properties similar to cocaine, potentially increasing drug abuse liability. OBJECTIVES: To examine the short- and long-term consequences of repeated vehicle, MPH, FLX, MPH + FLX, and cocaine treatment on gene expression in juvenile (postnatal days [PD] 20-34) and adult (PD 70-84) male mice. We further assessed whether juvenile drug treatment influenced subsequent sensitivity for nicotine in adulthood. METHODS: Juvenile and adult C57BL/6J mice received vehicle, MPH, FLX, MPH + FLX, or cocaine twice-daily for 15 consecutive days. Mice were sacrificed 24 h or 2 months after the last drug injection to assess drug-induced effects on the extracellular signal-regulated protein kinase-1/2 (ERK) pathway within the ventral tegmental area. Subsequent sensitivity for nicotine (0.05, 0.07, and 0.09 mg/kg) was measured using the place-conditioning paradigm (CPP) 24 h and 2 months after juvenile drug exposure. RESULTS: MPH + FLX, or cocaine exposure in juvenile mice increased mRNA expression of ERK2 and its downstream targets (CREB, cFos, and Zif268), and increased protein phosphorylation of ERK2 and CREB 2 months after drug exposure. Similar mRNA findings were observed in the adult-treated mice. Findings on gene expression 24 h following drug treatment were variable. Juvenile drug exposure increased preference for nicotine when tested in adulthood. CONCLUSIONS: Early-life MPH + FLX, or cocaine exposure similarly disrupts the ERK pathway, a signaling cascade implicated in motivation and mood regulation, and increases sensitivity for nicotine in adulthood.
RATIONALE: A common treatment strategy for pediatric attention deficit/hyperactivity disorder (ADHD) and major depressive disorder (MDD) is combined methylphenidate (MPH) and fluoxetine (FLX). This has raised concerns because MPH + FLX treatment may have pharmacodynamic properties similar to cocaine, potentially increasing drug abuse liability. OBJECTIVES: To examine the short- and long-term consequences of repeated vehicle, MPH, FLX, MPH + FLX, and cocaine treatment on gene expression in juvenile (postnatal days [PD] 20-34) and adult (PD 70-84) male mice. We further assessed whether juvenile drug treatment influenced subsequent sensitivity for nicotine in adulthood. METHODS: Juvenile and adult C57BL/6J mice received vehicle, MPH, FLX, MPH + FLX, or cocaine twice-daily for 15 consecutive days. Mice were sacrificed 24 h or 2 months after the last drug injection to assess drug-induced effects on the extracellular signal-regulated protein kinase-1/2 (ERK) pathway within the ventral tegmental area. Subsequent sensitivity for nicotine (0.05, 0.07, and 0.09 mg/kg) was measured using the place-conditioning paradigm (CPP) 24 h and 2 months after juvenile drug exposure. RESULTS:MPH + FLX, or cocaine exposure in juvenile mice increased mRNA expression of ERK2 and its downstream targets (CREB, cFos, and Zif268), and increased protein phosphorylation of ERK2 and CREB 2 months after drug exposure. Similar mRNA findings were observed in the adult-treated mice. Findings on gene expression 24 h following drug treatment were variable. Juvenile drug exposure increased preference for nicotine when tested in adulthood. CONCLUSIONS: Early-life MPH + FLX, or cocaine exposure similarly disrupts the ERK pathway, a signaling cascade implicated in motivation and mood regulation, and increases sensitivity for nicotine in adulthood.
Authors: Laurence L Greenhill; Peter S Jensen; Howard Abikoff; Jeffery L Blumer; Joseph Deveaugh-Geiss; Celia Fisher; Kimberly Hoagwood; Christopher J Kratochvil; Benjamin B Lahey; Thomas Laughren; James Leckman; Theodore A Petti; Kayla Pope; David Shaffer; Beneditto Vitiello; Charles Zeanah Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-04 Impact factor: 8.829
Authors: W Wargin; K Patrick; C Kilts; C T Gualtieri; K Ellington; R A Mueller; G Kraemer; G R Breese Journal: J Pharmacol Exp Ther Date: 1983-08 Impact factor: 4.030
Authors: Julie M Zito; Albert T Derivan; Christopher J Kratochvil; Daniel J Safer; Joerg M Fegert; Laurence L Greenhill Journal: Child Adolesc Psychiatry Ment Health Date: 2008-09-15 Impact factor: 3.033
Authors: Israel Garcia-Carachure; Francisco J Flores-Ramirez; Samuel A Castillo; Anapaula Themann; Miguel A Arenivar; Joshua Preciado-Piña; Arturo R Zavala; Mary Kay Lobo; Sergio D Iñiguez Journal: Neuropsychopharmacology Date: 2020-03-12 Impact factor: 7.853
Authors: Jennifer Ngolab; Liwang Liu; Rubing Zhao-Shea; Guangping Gao; Paul D Gardner; Andrew R Tapper Journal: J Neurosci Date: 2015-06-03 Impact factor: 6.167
Authors: Francisco J Flores-Ramirez; Israel Garcia-Carachure; David O Sanchez; Celene Gonzalez; Samuel A Castillo; Miguel A Arenivar; Anapaula Themann; Omar Lira; Minerva Rodriguez; Joshua Preciado-Piña; Sergio D Iñiguez Journal: J Psychopharmacol Date: 2018-10-18 Impact factor: 4.153
Authors: Valentina S Evsiukova; Daria Bazovkina; Ekaterina Bazhenova; Elizabeth A Kulikova; Alexander V Kulikov Journal: Int J Mol Sci Date: 2021-11-27 Impact factor: 5.923
Authors: Sergio D Iñiguez; Lace M Riggs; Steven J Nieto; Katherine N Wright; Norma N Zamora; Bryan Cruz; Arturo R Zavala; Alfred J Robison; Michelle S Mazei-Robison Journal: Sci Rep Date: 2015-10-09 Impact factor: 4.379